These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33449175)

  • 1. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI.
    Liu LH; Zhou GF; Lv H; Wang ZC; Rao SX; Zeng MS
    Eur Radiol; 2021 Aug; 31(8):5640-5649. PubMed ID: 33449175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy.
    Zhu HB; Xu D; Zhang XY; Li XT; Xing BC; Sun YS
    Ann Surg Oncol; 2022 Jun; 29(6):3938-3949. PubMed ID: 35013857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases-preliminary study.
    Matsushima S; Sato T; Nishiofuku H; Sato Y; Murata S; Kinosada Y; Era S; Inaba Y
    Clin Imaging; 2017; 41():1-6. PubMed ID: 27721090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
    Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
    Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
    Chun YS; Vauthey JN; Boonsirikamchai P; Maru DM; Kopetz S; Palavecino M; Curley SA; Abdalla EK; Kaur H; Charnsangavej C; Loyer EM
    JAMA; 2009 Dec; 302(21):2338-44. PubMed ID: 19952320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
    Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
    Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
    Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravoxel Incoherent Motion of Colon Cancer Liver Metastases for the Assessment of Response to Antiangiogenic Treatment: Results from a Pilot Study.
    Öz A; Server S; Koyuncu Sökmen B; Namal E; İnan N; Balcı NC
    Med Princ Pract; 2020; 29(5):429-435. PubMed ID: 31914438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted and hepatobiliary phase gadoxetic acid-enhanced quantitative MR imaging for identification of complete pathologic response in colorectal liver metastases after preoperative chemotherapy.
    Hosseini-Nik H; Fischer SE; Moulton CA; Karbhase G; Menezes RJ; Gallinger S; Jhaveri KS
    Abdom Radiol (NY); 2016 Feb; 41(2):231-8. PubMed ID: 26867904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric MRI with diffusion-weighted imaging in predicting response to chemotherapy in cases of osteosarcoma and Ewing's sarcoma.
    Saleh MM; Abdelrahman TM; Madney Y; Mohamed G; Shokry AM; Moustafa AF
    Br J Radiol; 2020 Nov; 93(1115):20200257. PubMed ID: 32706980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.
    Mazard T; Mollevi C; Loyer EM; Léger J; Chautard R; Bouché O; Borg C; Armand-Dujardin P; Bleuzen A; Assenat E; Lecomte T
    Cancer Imaging; 2024 Jun; 24(1):77. PubMed ID: 38886836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and
    Uutela A; Ovissi A; Hakkarainen A; Ristimäki A; Lundbom N; Kallio R; Soveri LM; Salminen T; Ålgars A; Halonen P; Ristamäki R; Nordin A; Blanco Sequeiros R; Rinta-Kiikka I; Lantto E; Virtanen J; Pääkkö E; Liukkonen E; Saunavaara J; Ryymin P; Lammentausta E; Osterlund P; Isoniemi H;
    ESMO Open; 2021 Aug; 6(4):100208. PubMed ID: 34325107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
    Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
    AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
    Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
    Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
    Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI
    Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
    Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
    Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
    Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S
    Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Treatment Response of Colorectal Cancer Liver Metastases to Conventional Lipiodol-Based Transarterial Chemoembolization Using Diffusion-Weighted MR Imaging: Value of Pretreatment Apparent Diffusion Coefficients (ADC) and ADC Changes Under Therapy.
    Lahrsow M; Albrecht MH; Bickford MW; Vogl TJ
    Cardiovasc Intervent Radiol; 2017 Jun; 40(6):852-859. PubMed ID: 28357571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.